Page 244
APPENDIX F
Approval Dates for Existing and Prospects for Development of New Antituberculosis Drugs and Vaccines
Please refer to the page image for an unflawed representation of this content.
|
Page 245
Please refer to the page image for an unflawed representation of this content.
|
Page 246
Novartis Pharmaceuticals
0
0
0
0
Ortho-McNeil Johnson & Johnson
0
Sending some candidate drugs out for in vitro testing; marketing experts not enthusiastic
0
Parke-Davis
0
0
0
0
Pfizer, Inc.
0
0
0
0
Pharmacia/Upjohn
0
?oxazolidinones
?oxazolidinones
0
Rhone-Poulene Rorer
0 0
0 0
Roche Pharmaceuticals
Had some preliminary work on IL-12 but gave up when in animals it increased CFU in lung
Had some preliminary work on IL-12 but gave up when in animals it increased CFU in lung
Had some preliminary work on IL-12 but gave up when in animals it increased CFU in lung
Had some preliminary work on IL-12 but gave up when in up when in animals it increased CFU in lung
Schering-Plough Corp.
0
0
0
0
G.D. Searle-Monsanto Co.
0
0
0
0
Smith Kline Beecham Pharmaceuticals
0
0
0
0
Warners Chilcott Laboratories
0
0
0
0
Warner Lambert Co.
0
0
0
0
Page 247
Please refer to the page image for an unflawed representation of this content.
|
There was a problem loading page 248.
Page 249
1) Activity: mole for mole as active as INH
2) Orally active
3) Bactericidal
4) Active vs. nongrowing organisms (e.g., M. tuberculosis cultured under anaerobic conditions)
5) Now in initial stages of testing
Ribozyme Pharmaceuticals
0
0
0
0
Sequella Corp.
-
Ethambutol analogs (3 candidates)
Clinical testing probably
Clinical testing probably
Vaccine: Has license for new experimental vaccine (Nature 400[6741]:269; 1999)
-
Shikemic acid pathway
0
0
(inhibitor)
-
New diagnostic being studied: A patch test that may be positive in patients with active disease but not in individuals with prior infection